Most human immunodeficiency virus (HIV) type 1 infections worldwide have occurred through heterosexual transmission [1] . Factors that significantly influence the amount of HIV-1 in vaginal secretions are probably important determinants of the risk of female-to-male sexual transmission. Studies elsewhere have shown that the amount of HIV-1 RNA in vaginal secretions is strongly correlated with that in plasma [2] [3] [4] [5] . In addition, antiretroviral therapy can reduce [5, 6] , whereas cervical inflammation and ulceration can increase [7, 8] , the amount of HIV-1 RNA in vaginal secretions by 1.0-2.0 log 10 . However, it is unclear whether hormonal changes during the menstrual cycle affect HIV-1 RNA levels in vaginal secretions.
Two recent publications have reported contradictory results about the effect of the menstrual cycle on HIV-1 in genital secretions. Mostad et al. [9] evaluated endocervical and vaginal swabs that were obtained daily during 1 menstrual cycle from each of 17 HIV-1-infected women to determine whether detection of HIV-1-infected cells changed during the phases of the menstrual cycle. They found no discernible pattern of HIV-1 DNA detection during the menstrual cycle and no significant association of HIV-1 DNA detection with serum estradiol and progesterone levels. In another study, Reichelderfer et al. [10] measured HIV-1 RNA levels in cervical mucus and cervicovaginal lavage samples that were obtained weekly over 8 weeks, beginning with menses, from 55 HIV-infected women. In contrast to the findings of Mostad et al. [9] , these investigators found that mean genital tract HIV-1 RNA levels declined during the first week after menses and increased over the next 2 weeks, which suggests a genital tract-specific hormonal effect on viral shedding. In addition to reporting contradictory results, these studies were limited by (1) use of proviral DNA detection rather than viral RNA quantification [9] , (2) the low frequency of HIV-1 detection [9, 10] , and (3) the use of highly active antiretroviral therapy by most study participants [10] .
The present study was designed to determine the effect of the menstrual cycle on the amount of cell-free HIV-1 RNA in vaginal secretions of HIV-1-infected women. During 33 menstrual cycles in 25 women, HIV-1 RNA levels were measured in plasma and vaginal lavage samples collected at 7, 14, and 21 days after initiation of menses, to compare virus levels during the follicular, ovulatory, and luteal phases. Plasma estradiol and progesterone levels were also measured to determine whether these levels were correlated with vaginal virus load (VVL) or plasma virus load. Informed consent was obtained from all patients in this study, and guidelines of the US Department of Health and Human Services were followed in the conduct of clinical research.
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Materials and Methods
Study population. This analysis includes data from examinations of women enrolled in the Emory Vaginal Ecology Study of HIV infection. HIV-1-infected women were asked to enroll in this study if they were 18-49 years of age, had a normal Pap smear within the previous 12 months, were expected to live at least 1 year, and either were not on antiretroviral therapy or had taken the same antiretroviral therapy for at least 3 months prior to enrollment. In addition, study participants who provided specimens for this analysis reported a history of regular menstrual periods every 26-32 days, with known dates of menses for the previous 2-3 cycles. Exclusion criteria were as described elsewhere [5] . Participants were requested to refrain from vaginal intercourse and the use of intravaginal medications for 72 h before their examinations.
Specimens. Blood and vaginal lavage samples were collected at 7, 14, and 21 days (^1 day) after the initiation of menses to represent the follicular, ovulatory, and luteal phases of the menstrual cycle. At each clinical exam, vaginal secretions were tested for the presence of seminal fluid, as described elsewhere [5, 11] . Lavage samples were obtained by introducing 10 mL of PBS into the vagina and collecting the pooled fluid in the posterior vaginal fornix, while carefully avoiding the cervix. Endocervical swabs were obtained to culture Neisseria gonorrhoeae and to test for Chlamydia trachomatis. Wet mounts were examined to detect Trichomonas vaginalis. In addition, 8 mL of venous blood was collected at each exam in a CPT vacutainer tube (Becton Dickenson) that contained acid-citratedextrose anticoagulant. Specimens were taken to the laboratory within 3 h for processing that day. Methods for processing samples, assaying for blood contamination, and extracting RNA were as described elsewhere [5, 12] .
Measurement of HIV-1 load. HIV-1 RNA was quantified in plasma and vaginal lavage samples by use of a quantitative-competitive (QC) reverse-transcriptase polymerase chain reaction (RT-PCR) assay, as described elsewhere [5, 13] . Optimized for measuring HIV-1 RNA in vaginal secretions, this assay includes an ultracentrifugation step, which concentrates virus and removes potential inhibitors. The lower limits of HIV-1 RNA quantification of this assay are 1000 copies per vaginal lavage and 800 copies/mL of plasma. The interassay variability of the QC RT-PCR assay for HIV-1 RNA is 0.5 log 10 . Therefore, virus loads differing by ,0.5 log 10 are considered to be equivalent in this analysis.
Measurement of estradiol and progesterone levels. Plasma estradiol and progesterone levels were determined by use of Immulite estradiol and progesterone kits (Diagnostic Products). Lower limits of detection for estradiol and progesterone were 10 pg/mL and 0.1 ng/mL, respectively.
Determination of HIV-1 cumulative variability. The cumulative variability was calculated to determine the amount of absolute change in VVL during the menstrual cycle. Cumulative variability is the sum of the absolute values of the log 10 changes in virus loads from day 7 to day 14 and from day 14 to day 21, as calculated by the following equation: j log 10 ðVVL day 7 Þ 2 log 10 ðVVL day 14 Þj þ j log 10 ðVVL day 14 Þ 2 log 10 ðVVL day 21 Þj. Changes in VVL during a menstrual cycle were categorized into 4 levels of cumulative variability. For this analysis, lavage samples with undetectable virus load were assigned a value of 100 copies per lavage, and samples with detectable but unquantifiable virus load were assigned a value of 500 copies per lavage. In table 1, the samples from 6 cycles with undetectable VVLs on days 7, 14, and 21 are included in the ,0.5 log 10 category, because changes in virus loads could not be measured.
Statistical methods. Analyses of week-to-week differences in plasma and vaginal lavage HIV-1 RNA levels were performed by use of the Wilcoxon rank sum test. The power to detect a difference in median VVLs from week to week was calculated by use of SOLO Power Analysis software (BMDP Statistical Software). Correlations between HIV-1 RNA levels in vaginal lavage samples and estradiol and progesterone concentrations in blood plasma were determined by use of Spearman's rank correlation coefficients, and the statistical significance was assessed with t tests. Statistical significance was defined as P , :05.
Results
Study participants. A total of 99 matched blood and vaginal lavage samples were collected during 33 menstrual cycles of 25 HIV-1-infected women. Samples were provided by 17 women during 1 menstrual cycle and by 8 women during 2 cycles. Five (20%) of 25 women had been taking antiretroviral therapy for at least 3 months prior to enrollment and did not change therapy during the study. However, 4 (80%) of 5 women had detectable plasma virus loads and VVLs. The mean and median CD4 + T lymphocyte counts in blood were 254 and 262 cells/mL, respectively (range, 2-681 cells/mL). Only 4 (4%) of the 99 lavage samples had .1% of HIV-1 RNA derived from blood contamination, as determined by measuring the amount of hemoglobin in each lavage [5] . N. gonorrhoeae, C. trachomatis, and T. vaginalis were found in 0%, 1%, and 10% of lavage samples, respectively. None of the women had evidence of seminal fluid in vaginal secretions.
HIV-1 RNA in plasma. HIV-1 RNA was detected in 96 (97%) of 99 plasma samples (table 1). The 3 samples with undetectable plasma HIV-1 RNA were collected from 1 patient (patient 1022). The mean and median HIV-1 RNA levels in plasma were 2:2 £ 10 5 and 7:5 £ 10 4 copies/mL, respectively (range, ,800-1:6 £ 10 6 copies/mL). Week-to-week variability of plasma virus loads was ,0.5 log 10 in 58 (88%) of 66 weekly intervals. In the present study, plasma HIV-1 RNA levels did not change significantly from week to week during the menstrual cycle (day 7 to day 14, P ¼ :9; day 14 to day 21, P ¼ 1:0).
HIV-1 RNA in vaginal secretions. HIV-1 RNA was detected in 76 (77%) of 99 vaginal lavage samples (table 1) . The absolute change in VVLs, as measured by cumulative variability, ranged from ,0.5 to 3.7 log 10 and was .2 log 10 for 7 (21%) of 33 cycles, 1-2 log 10 for 8 (24%) cycles, 0.5 to ,1 log 10 for 5 (15%) cycles, and ,0.5 log 10 for 13 (39%) cycles. Six (50%) of 12 cycles with a cumulative variability of ,0.5 log 10 had undetectable HIV-1 RNA in vaginal lavage samples from days 7, 14, and 21. Four (12%) of 33 cycles had HIV-1 virus loads that fluctuated from undetectable to detectable during days 7-21.
These results indicate that the amount of absolute change in VVLs during the menstrual cycle was variable.
To determine whether HIV-1 RNA levels in vaginal lavage samples changed significantly from week to week, median VVLs were compared from days 7, 14, and 21. Our sample size of 33 menstrual cycles gave an 80% power to detect a difference of >0.5 log 10 in median VVLs from week to week. For these cycles, the median VVL decreased 0.56 log 10 , from 2:2 £ 10 4 total copies per lavage on day 7 to 6:0 £ 10 3 total copies on day 14. From day 14 to day 21, the median VVL increased 0.34 log 10 to 1:3 £ 10 4 total copies per lavage. These changes were not significant (day 7 to day 14, P ¼ :49; day 14 to day 21, P ¼ :99). In addition, the week-to-week changes in median VVLs for the 20 menstrual cycles with a measurable cumulative variability of .0.5 log 10 were not significant (day 7 to day 14, P ¼ :42; day 14 to day 21, P ¼ :90).
To identify possible patterns of change in HIV-1 RNA levels during the menstrual cycle, we compared the proportion of cycles that showed weekly increases, decreases, or no measurable change in VVLs. From day 7 to day 14, VVLs increased during 5 (15%) cycles, decreased during 13 (39%) cycles, and showed no measurable change during 15 (45%) cycles (figure 1). From day 14 to day 21, VVLs increased during 5 (15%) cycles, decreased during 5 (15%) cycles, and showed no measurable change during 23 (70%) cycles. In addition, when consecutive weekly changes in VVL during each menstrual cycle were compared, all 9 possible patterns of change were present. Of the 5 cycles that showed an increase in VVL from day 7 to 14, 1 increased, 2 decreased, and 2 had no measurable change from day 14 to day 21 (figure 2A). Of the 13 cycles that showed a decrease from day 7 to 14, 4 increased, 1 decreased, and 8 had no measurable change from day 14 to day 21 (figure 2B). Of the 15 cycles that had no measurable change from day 7 to day 14, 1 increased, 2 decreased, and 12 had no measurable change from day 14 to day 21 ( figure 2C ). These results indicate that there was no discernible pattern of change in VVLs during the menstrual cycle. To determine whether women have similar patterns of change in VVLs during different menstrual cycles, we compared patterns of change between cycles in the 8 women who provided samples from 2 cycles (figure 3). From day 7 to day 14, 5 (63%) of 8 women had similar patterns of change during both cycles; 4 women (patients 55, 71, 1016, and 1033) had a decrease, and 1 woman (patient 1032) had no measurable change in VVL. However, from day 14 to day 21, only 2 of these 5 women (patients 55 and 1033) had similar patterns in both cycles. For both women, VVLs decreased from day 7 to day 14 and showed no measurable change from day 14 to day 21 in each of the 2 cycles. These results indicate that there was no consistent pattern of change in VVLs during 2 menstrual cycles in the same woman.
Plasma estradiol and progesterone levels. Estradiol (pg/ mL) and progesterone (ng/mL) levels were measured in 96 (97%) of 99 plasma samples (table 2) . Plasma estradiol levels increased from day 7 to days 14 and 21 during 24 (80%) of 30 menstrual cycles, and progesterone levels were at least 6.5 ng/ mL on day 21 in 18 (56%) of 32 cycles, as expected in a normal ovulatory cycle. Plasma estradiol and progesterone levels were not correlated with plasma virus load (P ¼ :19 and P ¼ :42, respectively) or VVL (P ¼ :26 and P ¼ :93, respectively) (figure 4). Furthermore, plasma estradiol and progesterone levels were not correlated with weekly changes in the amount of HIV-1 RNA in plasma samples (day 7 to day 14, P ¼ :64 and P ¼ :18, respectively; day 14 to day 21, P ¼ :20 and P ¼ :81, respectively) and vaginal lavage samples (day 7 to day 14, P ¼ :96 and P ¼ :53, respectively; day 14 to day 21, P ¼ :53 and P ¼ :52, respectively).
Discussion
The current study was designed to determine whether hormonal changes during the menstrual cycle affect HIV-1 levels in vaginal secretions. Studies elsewhere have shown that the length of the menstrual cycle and the duration of menstrual bleeding are not significantly different in HIV-infected and -uninfected women, which suggests that most HIV-infected women ovulate monthly and have intact hypothalamic-pituitary-ovarian axes [14] . In the present study, the 25 HIV-1-infected women were selected on the basis of a history of 26-32-day cycles with normal menstrual bleeding, and plasma estradiol and progesterone levels suggested that most of the cycles during the study were ovulatory [15] . In addition, because only 15% of the women in the study were taking antiretroviral therapy and a sensitive QC RT-PCR technique was used to measure HIV-1 RNA, .75% of vaginal lavage samples had detectable HIV-1 RNA. Moreover, 90% of study participants did not have cervicovaginal infections, and only 4 vaginal lavage samples had .1% of total HIV-1 RNA derived from blood. As a result, neither genital infections nor blood contamination had an important effect on HIV-1 levels in vaginal secretions during the study.
In the present study, we found that hormonal changes during the menstrual cycle do not have a significant effect on HIV-1 RNA levels in vaginal secretions. During 33 menstrual cycles in 25 HIV-1-infected women, HIV-1 RNA levels in vaginal lavage samples collected at days 7, 14, and 21 after initiation of menses were not significantly different. Also, no discernible pattern was found in changes of VVL during the menstrual cycle. In addition, plasma estradiol and progesterone levels were not correlated with plasma virus load or VVL. However, all 6 women who had undetectable VVLs on day 7 also had undetectable VVLs on days 14 and 21.
In our study, the comparatively high levels of virus detection and quantification in samples that lacked blood contamination allowed us to study the effect of the menstrual cycle on HIV-1 levels in vaginal secretions more definitively than has been done in studies elsewhere. Goulston et al. [4] found that detection of HIV-1 DNA and the amount of HIV-1 RNA in cervical swabs were not affected by menstruation, but HIV-1 RNA and DNA were detected in only 22 (46%) and 7 (15%) of 48 samples, respectively. Mostad et al. [9] found no discernible pattern of genital tract shedding with phase of the menstrual cycle. Although daily collection of samples enabled Mostad et al. to monitor HIV-1 DNA detection during the menstrual cycle, HIV-1-infected cells were detected in only 207 (46%) of 450 cervical swabs and 74 (16%) of 449 vaginal swabs, and cellfree HIV-1 RNA was not quantified. In contrast to the results of our study, Reichelderfer et al. [10] found that HIV-1 RNA levels in cervicovaginal lavage and endocervical cytobrush specimens were highest during menses and lowest the following week, which suggests that HIV-1 RNA levels in the female genital tract vary with the menstrual cycle. However, 287 (96%) of 299 cytobrush specimens in their study tested positive for blood, and the amount of blood contamination was associated with HIV-1 RNA levels. Despite blood contamination, HIV-1 RNA was detected in only 208 (51%) of 407 cytobrush specimens and 140 (34%) of 412 cervicovaginal lavage samples.
Our study has several limitations. The relatively small sample size could have affected our ability to identify week-to-week differences in the median VVL. However, our sample size of 33 menstrual cycles gave an 80% power to detect a difference of >0.5 log 10 in median VVLs from week to week. Moreover, because there was no predictable increase or decrease in VVLs during the menstrual cycle (figures 2 and 3), it is highly unlikely that a pattern of week-to-week changes of ,0.5 log 10 existed. Also, the effect of the menstrual cycle on virus load in vaginal secretions could have been more accurately measured if samples were collected daily during days 7-28 of the menstrual cycle. However, daily sampling was not done because the kinetics of viral repopulation in genital secretions are not known. Daily monitoring of plasma follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone levels would have provided more information to determine whether cycles were ovulatory [15] . Furthermore, in addition to vaginal lavage samples, (15 January) cervical mucus samples could have been assayed for HIV-1 RNA. However, we have shown elsewhere that HIV-1 RNA levels in cervical mucus and vaginal secretions are significantly correlated [5] . Finally, VVL was not measured during menstrual bleeding. It is important to note that intercourse during menstrual bleeding may increase the risk for female-to-male transmission, because the presence of blood probably increases the virus load in vaginal secretions.
Factors that significantly influence the amount of HIV-1 in vaginal secretions are likely to be important determinants of the risk of female-to-male sexual transmission. In the present study, we determined that the menstrual cycle does not have a significant effect on HIV-1 RNA levels in vaginal secretions. We also found that the amount of change in VVLs during the cycle was variable but not because of genital infections or antiretroviral therapy. Consequently, nonmenstrual factors, such as fluctuations of cytokine and chemokine concentrations in the genital tract, determine HIV-1 levels in vaginal secretions. Additional research is needed to identify these factors. Comparison of plasma and vaginal virus loads (VVLs) and plasma estradiol and progesterone levels. A, Plasma virus loads and plasma estradiol levels. B, VVLs and plasma estradiol levels. C, Plasma virus loads and plasma progesterone levels. D, VVLs and plasma progesterone levels. The lower limits for quantification of human immunodeficiency virus type 1 RNA in plasma and vaginal secretions were 800 copies/mL and 1000 copies per lavage, respectively, as indicated by the horizontal dashed lines. The lower limits for quantification of plasma estradiol and progesterone levels were 10 pg/mL and 0.1 ng/mL, respectively, as indicated by the vertical dashed lines.
